On Tuesday, Shares of Verisk Analytics, Inc. (NASDAQ:VRSK), lost -0.57% to $80.82.
3E Company, declared that it has won the Content Partner of the Year category of the Enablon Excellence Awards. Enablon is the world`s leading provider of sustainability, EH&S, and operational risk administration software. This is the second successive year that 3E has won the award. 3E Company is a Verisk Analytics (VRSK) business.
Enablon`s sustainability platform comprises a powerful chemical administration solution (CMS) powered by 3E Integrated Content, creating an optimized solution for the administration of chemical substances in addition to regulatory compliance activities and monitoring. The integrated solution streamlines and empowers better regulatory administration and insights by providing:
- immediate determination of regulated materials on-site
- up-to-date information for compiling regulatory reports
- instant access to current safety data sheets (SDSs)
“We are delighted to receive this award from Enablon. As companies around the globe strive to manage their regulatory obligations, industry leaders like 3E and Enablon stand ready to assist them create intelligent compliance strategies, while also increasing efficiency and mitigating risk,” said Uday Virkud, president and CEO, 3E Company.
Verisk Analytics, Inc. provides information about risk to professionals in insurance, healthcare, financial services, government, supply chain, and risk administration in the United States and internationally. The companys Risk Assessment segment offers solutions to P&C insurance customers and focuses on decision making processes in its risk analysis framework, counting prediction of loss, and selection and pricing of risk.
Shares of Liberty Interactive Group (NASDAQ:QVCA), declined -1.95% to $26.70, during its last trading session.
Liberty Interactive Corporation’s, President and Chief Executive Officer, Greg Maffei, will host a conference call to discuss results for the third quarter of 2015 on Wednesday, November 4th, at 5:15 p.m. (E.S.T.). Following prepared remarks, the company will host a brief Q&A session during which administration will accept questions regarding both Liberty Interactive Corporation and Liberty TripAdvisor Holdings. During the call, Mr. Maffei may discuss the financial performance and outlook of both companies, in addition to other forward looking matters.
Liberty Interactive Corporation, through its auxiliaries, engages in the video and on-line commerce industries in North America, Europe, and Asia. It markets and sells various consumer products primarily through live televised shopping programs, Websites, and mobile applications.
At the end of Tuesday’s trade, Shares of Intrexon Corp (NYSE:XON), lost -4.11% to $31.06.
Fibrocell Science, Inc., (FCSC), an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, recently declared that John Maslowski, Senior Vice President of Scientific Affairs, will present on Thursday, October 8 at 4:45 p.m. PDT at the annual Partnering Forum, part of the Stem Cell Meeting on the Mesa to be held October 7-9 in La Jolla, California.
This regenerative medicine conference brings together senior executives and top decision makers from the industry’s scientific community with the aim of advancing and translating cutting-edge research into potential treatments and cures.
Mr. Maslowski’s presentation will be webcast live under the Investors & Media section of Fibrocell’s website at fibrocell.com/investors/events-and-presentations, and also posted on the Alliance for Regenerative Medicine’s (ARM) website shortly after the event. Please visit Fibrocell’s website several minutes preceding to the start of the broadcast to ensure adequate time for any software download that may be necessary.
Fibrocell Science, Inc. (FCSC) is an autologous cell and gene therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell’s most advanced product candidate, azficel-T, uses its proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring. In partnership with Intrexon Corporation (XON), a leader in synthetic biology, Fibrocell is also developing gene therapies for skin diseases using gene-modified autologous fibroblasts.
Intrexon Corporation, a biotechnology company, operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that comprise of key genetic components.
Finally, Exterran Holdings, Inc. (NYSE:EXH), ended its last trade with 11.52% gain, and closed at $23.04.
Exterran Holdings, declared an update to the planned financing in connection with its formerly declared separation.
In November 2014, Exterran Holdings declared that it intends to separate its international contract operations, international aftermarket services and global fabrication businesses into a standalone, publicly traded company named Exterran Corporation. Upon completion of the spin-off, Exterran Holdings, which will continue to own and operate its contract operations and aftermarket services businesses in the United States, will be renamed Archrock, Inc.
Exterran Holdings, Inc., together with its auxiliaries, provides operations, maintenance, services, and equipment for the oil and natural gas production, processing, and transportation applications. The company’s North America Contract Operations segment provides natural gas compression services. Its International Contract Operations segment engages in the engineering, procurement, and on site construction of natural gas compression stations and/or crude oil or natural gas production and processing facilities.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.